Literature DB >> 26821783

A three-groups model for high-throughput survival screens.

Benjamin A Shaby1, Gaia Skibinski2, Michael Ando2, Eva S LaDow3, Steven Finkbeiner2.   

Abstract

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative condition characterized by the progressive deterioration of motor neurons in the cortex and spinal cord. Using an automated robotic microscope platform that enables the longitudinal tracking of thousands of single neurons, we examine the effects a large library of compounds on modulating the survival of primary neurons expressing a mutation known to cause ALS. The goal of our analysis is to identify the few potentially beneficial compounds among the many assayed, the vast majority of which do not extend neuronal survival. This resembles the large-scale simultaneous inference scenario familiar from microarray analysis, but transferred to the survival analysis setting due to the novel experimental setup. We apply a three-component mixture model to censored survival times of thousands of individual neurons subjected to hundreds of different compounds. The shrinkage induced by our model significantly improves performance in simulations relative to performing treatment-wise survival analysis and subsequent multiple testing adjustment. Our analysis identified compounds that provide insight into potential novel therapeutic strategies for ALS.
© 2016, The International Biometric Society.

Entities:  

Keywords:  Bayesian; High-throughput data; Mixture model; Multiple testing; Shrinkage; Survival analysis

Mesh:

Year:  2016        PMID: 26821783      PMCID: PMC4965338          DOI: 10.1111/biom.12479

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  10 in total

1.  Bayesian analysis and model selection for interval-censored survival data.

Authors:  D Sinha; M H Chen; S K Ghosh
Journal:  Biometrics       Date:  1999-06       Impact factor: 2.571

2.  Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death.

Authors:  Montserrat Arrasate; Siddhartha Mitra; Erik S Schweitzer; Mark R Segal; Steven Finkbeiner
Journal:  Nature       Date:  2004-10-14       Impact factor: 49.962

Review 3.  Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).

Authors:  R G Miller; J D Mitchell; M Lyon; D H Moore
Journal:  Cochrane Database Syst Rev       Date:  2007-01-24

4.  Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis.

Authors:  Manuela Neumann; Deepak M Sampathu; Linda K Kwong; Adam C Truax; Matthew C Micsenyi; Thomas T Chou; Jennifer Bruce; Theresa Schuck; Murray Grossman; Christopher M Clark; Leo F McCluskey; Bruce L Miller; Eliezer Masliah; Ian R Mackenzie; Howard Feldman; Wolfgang Feiden; Hans A Kretzschmar; John Q Trojanowski; Virginia M-Y Lee
Journal:  Science       Date:  2006-10-06       Impact factor: 47.728

Review 5.  Excitatory amino acids as a final common pathway for neurologic disorders.

Authors:  S A Lipton; P A Rosenberg
Journal:  N Engl J Med       Date:  1994-03-03       Impact factor: 91.245

6.  TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis.

Authors:  Tetsuaki Arai; Masato Hasegawa; Haruhiko Akiyama; Kenji Ikeda; Takashi Nonaka; Hiroshi Mori; David Mann; Kuniaki Tsuchiya; Mari Yoshida; Yoshio Hashizume; Tatsuro Oda
Journal:  Biochem Biophys Res Commun       Date:  2006-10-30       Impact factor: 3.575

7.  Cytoplasmic mislocalization of TDP-43 is toxic to neurons and enhanced by a mutation associated with familial amyotrophic lateral sclerosis.

Authors:  Sami J Barmada; Gaia Skibinski; Erica Korb; Elizabeth J Rao; Jane Y Wu; Steven Finkbeiner
Journal:  J Neurosci       Date:  2010-01-13       Impact factor: 6.167

8.  Racing against the clock: recognizing, differentiating, diagnosing, and referring the amyotrophic lateral sclerosis patient.

Authors:  Steven J Shook; Erik P Pioro
Journal:  Ann Neurol       Date:  2009-01       Impact factor: 10.422

Review 9.  American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.

Authors:  Eric P Winer; Clifford Hudis; Harold J Burstein; Antonio C Wolff; Kathleen I Pritchard; James N Ingle; Rowan T Chlebowski; Richard Gelber; Stephan B Edge; Julie Gralow; Melody A Cobleigh; Eleftherios P Mamounas; Lori J Goldstein; Timothy J Whelan; Trevor J Powles; John Bryant; Cheryl Perkins; Judy Perotti; Susan Braun; Amy S Langer; George P Browman; Mark R Somerfield
Journal:  J Clin Oncol       Date:  2004-11-15       Impact factor: 44.544

Review 10.  Advances in motor neurone disease.

Authors:  Dirk Bäumer; Kevin Talbot; Martin R Turner
Journal:  J R Soc Med       Date:  2014-01       Impact factor: 5.344

  10 in total
  4 in total

Review 1.  Cell death assays for neurodegenerative disease drug discovery.

Authors:  Jeremy W Linsley; Terry Reisine; Steven Finkbeiner
Journal:  Expert Opin Drug Discov       Date:  2019-06-10       Impact factor: 6.098

2.  Automated four-dimensional long term imaging enables single cell tracking within organotypic brain slices to study neurodevelopment and degeneration.

Authors:  Jeremy W Linsley; Atmiyata Tripathi; Irina Epstein; Galina Schmunk; Elliot Mount; Matthew Campioni; Viral Oza; Mariya Barch; Ashkan Javaherian; Tomasz J Nowakowski; Siddharth Samsi; Steven Finkbeiner
Journal:  Commun Biol       Date:  2019-05-01

Review 3.  Functional genomics, genetic risk profiling and cell phenotypes in neurodegenerative disease.

Authors:  Steven Finkbeiner
Journal:  Neurobiol Dis       Date:  2020-09-23       Impact factor: 5.996

4.  Superhuman cell death detection with biomarker-optimized neural networks.

Authors:  Jeremy W Linsley; Drew A Linsley; Josh Lamstein; Gennadi Ryan; Kevan Shah; Nicholas A Castello; Viral Oza; Jaslin Kalra; Shijie Wang; Zachary Tokuno; Ashkan Javaherian; Thomas Serre; Steven Finkbeiner
Journal:  Sci Adv       Date:  2021-12-08       Impact factor: 14.136

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.